Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Catherine Dive-Pouletty"'
Publikováno v:
Cancer Reports, Vol 6, Iss 12, Pp n/a-n/a (2023)
Abstract Background Surgical complications and particularly infections after digestive cancer surgery remain a major health and economic problem and its burden in France is not well documented. Aims The aim of this study was to analyse recent data re
Externí odkaz:
https://doaj.org/article/c3ec3a1383d74bc68ff4c37e8a1472c8
Autor:
Julie Lemale, Jean-Luc Decline, Catherine Dive-Pouletty, Chantal Touboul, Nadège Pichon, Christophe Dupont
Publikováno v:
Nutrients; Volume 14; Issue 6; Pages: 1203
Symptoms related cow’s milk proteins allergy (CMPA) usually improve between two to four weeks following an elimination diet, firstly with extensively hydrolyzed formulas (eHF). The aim of the EVA study was to observe the evolution of CMPA-related s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b88195f04d2611db37616ad4fc28a3d6
Autor:
Patrick Vermersch, Steven Hass, Catherine Dive-Pouletty, Jeremy Hobart, Patricia K. Coyle, Sylvie Bozzi
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: The Treatment Satisfaction Questionnaire for Medication (TSQM) was designed to assess patient treatment satisfaction in chronic diseases. Its performance has not been examined in multiple sclerosis (MS). The 14 items of the TSQM cover fou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::180834156727dfbfadd862a728fa8026
https://doi.org/10.1177/1352458516657441
https://doi.org/10.1177/1352458516657441
Autor:
Paul O'Connor, Mathias Mäurer, Giancarlo Comi, Mark S. Freedman, Sylvie Bozzi, Catherine Dive-Pouletty, Tomas Olsson, Aaron E. Miller, Jerry S. Wolinsky, Ludwig Kappos
Publikováno v:
Multiple Sclerosis and Related Disorders. 7:33-40
Two pivotal phase 3 teriflunomide studies provided data on relapses, fatigue, and health-related quality of life (HRQoL) in patients with relapsing forms of multiple sclerosis (MS).Using pooled data from the TEMSO (NCT00134563) and TOWER (NCT00751881
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04665f54d5e61aa6f0928f40a158175b
Autor:
Richard A L Macdonell, Sylvie Bozzi, Jerry S. Wolinsky, Tomas Olsson, Paul O'Connor, Catherine Dive-Pouletty, Mathias Mäurer, Mark S. Freedman, Giancarlo Comi, Ludwig Kappos, Aaron E. Miller
Publikováno v:
Journal of Neurology
Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing–remitting multiple sclerosis. This post hoc analysis of the Phase III TOWER study evaluated the effects of teriflunomide treatment on five severe relapse out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bee957bb13a6ef1eef062808dd72893b
http://europepmc.org/articles/PMC4155167
http://europepmc.org/articles/PMC4155167
Autor:
Karthinathan Thangavelu, Mark S. Freedman, Xavier Montalban, Steven Hass, Aaron E. Miller, Thomas Leist, Catherine Dive-Pouletty
Publikováno v:
Multiple sclerosis and related disorders. 10
Dimethyl fumarate (DMF), fingolimod, and teriflunomide are oral disease-modifying therapies (DMTs) indicated for the treatment of relapsing-remitting multiple sclerosis. Despite well-established limitations of cross-trial comparisons, DMTs are still
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35c0622e0ef360cfdc98f972edcbe0eb
https://pubmed.ncbi.nlm.nih.gov/27919491
https://pubmed.ncbi.nlm.nih.gov/27919491
Autor:
Martin Stangel, Mathias Mäurer, Karthinathan Thangavelu, Thomas Leist, S. Bozzi, Philippe Truffinet, Catherine Dive-Pouletty, Richard A L Macdonell, Mark S. Freedman
Publikováno v:
Value in Health. 18(3)
1Comprehensive Multiple Sclerosis Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 2Hannover Medical School, Hannover, Germany; 3Austin Health, Heidelberg, VIC, Australia; 4Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Ger
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73bccf7634fafece448184d1e021255b
Publikováno v:
Value in Health. 17(7)
1University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain; 3Icahn School of Medicine at Mount Sinai, New York, NY, USA; 4Genzy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97ca66806a16c20a5c7b60012b92d8a8
Autor:
Paul O'Connor, Gaelle Bego-Le-Bagousse, Fred D. Lublin, Christian Confavreux, Giancarlo Comi, Ludwig Kappos, Tomas Olsson, Aaron E. Miller, Mark S. Freedman, Jerry S. Wolinsky, Catherine Dive-Pouletty
Publikováno v:
Journal of Neurology
Multiple sclerosis (MS) relapses impose a substantial clinical and economic burden. Teriflunomide is a new oral disease-modifying therapy approved for the treatment of relapsing MS. We evaluated the effects of teriflunomide treatment on relapse-relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b8056adf49bc6653c847b9fa279f9e5
Autor:
Ludwig Kappos, Mark S. Freedman, Giancarlo Comi, Christian Confavreux, Jerry S. Wolinsky, Aaron Miller, Catherine Dive-Pouletty, Gaelle Bego-Le-Bagousse, Tomas Olsson, Fred D. Lublin, Paul O'Connor
Publikováno v:
Neurology. 78:S30.003-S30.003
Objective: To assess whether teriflunomide reduces the occurrence of relapses with sequelae and relapses leading to hospitalization. Background Incomplete recovery from relapses leads to some degree of disability. Teriflunomide is a novel oral diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43a1e2ff7a2e5de75845b1d368ee88f4
https://doi.org/10.1212/wnl.78.1_meetingabstracts.s30.003
https://doi.org/10.1212/wnl.78.1_meetingabstracts.s30.003